ZEJULA (niraparib) Extends PARP Inhibitor
Therapy to More Women1

EXPLORE WHAT ZEJULA CAN OFFER PATIENTS WITH OVARIAN CANCER
IN THE FOLLOWING INDICATIONS1:

FDA-approved indications for ZEJULA1

ZEJULA (niraparib) FDA approved indication chart
ZEJULA (niraparib) FDA approved indication chart

In QUADRA, HRD-positive status (HRD+) was determined using the Myriad myChoice® CDx as either tBRCAm and/or GIS+ (genomic instability score [GIS] ≥42).1

Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA.


ZEJULA is the only once-daily oral
PARP inhibitor monotherapy for ovarian cancer1-3